Ovaries: In Sickness and Health



Mr N Pisal Consultant Gynaecologist The Portland Hospital

- How to assess ovarian function?
- AMH
- PCOS
- Ovarian pain
- Ovarian cysts
- Ovarian screening
- Menopause



- All of the follicles are made in fetal life!
 - At 6 months of fetal life: 3.5 million follicles
 - At birth: 1 million
 - At puberty: 400,000
 - At 50y: 1000
 - Less than 500 are used for ovulation!
- No of incessant ovulations relate to risk of ovarian cancer.
 - OCP, multiparity \rightarrow lower lifetime risk
 - Ovulation induction →increased risk
- Ovaries are the only organs in the abdomen without a peritoneal covering. That's why ovarian cancer spreads quickly and also why ovaries are a common site of metastatic tumours (Krukenberg's)



- FSH, LH, E2
- AMH
- Antral follicle count
- Ovarian size
- Age
- Smoking



- Function of ovarian reserve
- Not cycle dependent
- Produced by antral follicles
- AMH: Declines with age
- Increased in PCOS
- Smoking: Quitting improves AMH
- AMH can identify women who should start trying for pregnancy soon
- Low AMH → Reduced success rates for IVF
- However, no evidence about chances conceiving naturally



- Oligo/anovulation
- Hyperandrogenemia: clinical or biochemical
- Polycystic ovaries on USS
- 2 out of 3 criteria needed for diagnosis



- PCO appearance: 20-30% of general population
- But only 5% of general population will have PCOS
- Features of PCOS
 - Oligomenorrhoea: 66%
 - Hirsuitism: 66%
 - Acne: 35%
 - Infertility: 50%
 - Obesity: 38%
 - Slim women with PCOS: 33%
 - Increased LH: 40%
 - Increased T: 30%




- Stay slim
 - Weight loss through exercise and Low-GI diet
- If NOT trying to get pregnant
 - COCP &/or Metformin
 - Mirena or 4 withdrawal bleeds /yr with Progesterone
- If trying to get pregnant
 - Reassure \rightarrow 50% get pregnant spontaneously
 - Ovulation induction with clomiphene or gonadotrophins
 - Risk of multiple pregnancy \rightarrow follicular tracking




Ovarian pain






- Mid-cycle pain
- Unilateral
- NSAIDs
- OCPs
















- Pain because of bleeding / torsion / rupture
- Three types: Functional / Benign / Malignant
- USS characteristics important:
 - Size / complexity / irregularity / bilateral / doppler / free fluid
- In women <45, simple 6cm cyst: Repeat USS 6wks
- If suspicious features / older women / persistent simple cyst: CA125 + Refer








Postmenopausal: 3 Premenopausal: 1 **X** Value of CA125 (upper limit of n = 35) **X** Ultrasound features s/o malignancy: 3 S/o Benign mass: 1

RMI

<250: Low risk >450: High risk 250-450: Intermediate risk









- Ectopic endometrium
- Common sites: POD, Uterosacral ligaments, ovaries, pelvis, bowel
- Classical symptoms: Dysmenorrhoea + Dyspareunia
- Examination: Uterosacral nodularity in post fornix, adnexal tenderness, occasional RV fixed tender uterus
- USS: Useful if ovarian endometrioma present
- Laparoscopy: Diagnostic + Surgical treatment
- Medical Treatment:
 - Pseudopregnancy (Tricycle OCP) OR
 - Pseudomenopause (GnRH analogues) regimens



- Most women with chronic pelvic pain will benefit from OCP
 - Dysmenorrhoea
 - Ovarian Cysts
 - Endometriosis
 - Adenomyosis
 - PCOS



News

How ovarian cancer delays are costing hundreds of lives

Martin Barrow Health Editor

Hundreds of women are dying needlessly every year because of avnidable delays in the diagnosis of ovarian cancer, a study published today says.

Ovarian cancer is the fourth must common cause of cancer iteallis

among women, after lung, breast and bowel cancer, claiming 4300 lives every year, and the UK has a particularly poor record compared with other boromean countries.

Now a study of those living and working with ovarian cancer in the UK suggests that about one quarter of women



Eather Matthews walled seven frustrating months, but is now free of cancer



The slent


NHS National Institute for Health and Clinical Excellence

Quick reference guide

Issue date: April 2011

Ovarian cancer

The recognition and initial management of ovarian cancer





- Diagnostic criteria (98% PPV)
 - At least 12 weeks of continuous or recurrent abdominal pain associated with at least two of the following:
 - Pain relieved with defecation
 - Associated with a change in frequency of stool
 - Associated with change in appearance or form of stool

Woman reports having any of the following symptoms persistently or frequently – particularly more than 12 times per month (especially if she is 50 or over)⁵:

- persistent abdominal distension ("bloating")
- feeling full (early satiety)
- pelvic or abdominal pain

 Increased uninary urgency and/or frequency

Or:

Woman is 50 or over and has had symptoms within the last 12 months that suggest IBS⁶




Ovarian Cancer Screening in the General Population




| Site | Annual Incidence | Mortality Incidence |
|----------------|------------------|---------------------|
| Breast | 40,740 | 0.32 |
| Lung | 14,878 | 0.87 |
| Colorectal | 15,939 | 0.48 |
| Ovary | 6,663 | 0.67 |
| Uterine corpus | 5,490 | 0.18 |
| Melanoma | 3,833 | 0.19 |
| Pancreas | 3,637 | 0.99 |
| Stomach | 3,454 | 0.75 |
| Bladder | 3,302 | 0.55 |
| Cervix | 3,045 | 0.39 |








The challenge of ovarian cancer screening



1 in 2,500 women per year develop ovarian cancer





5 operations for each patient detected with ovarian cancer



There is one group of women where screening for ovarian cancer may be beneficial.





Less than 10% of breast and ovarian cancers can be attributed to a genetic predisposition to the disease



- BRCA1 / BRCA2
 - Autosomal dominant
 - Breast and/or ovarian cancer
 - Earlier age onset
- HNPCC (LYNCH 2)
 - Autosomal dominant
 - Colorectal cancer (80% lifetime risk)
 - Ovarian cancer (10% lifetime risk)
 - Endometrial cancer (40-55% lifetime risk)
 - Earlier age onset
- OTHER GENES
 - ?Multiple / low penetrance



| | Breast Cancer | Ovarian Cancer |
|-------------------------|---------------|----------------|
| General population | 8% | 2% |
| One 1st degree relative | >8% | 4% |
| HNPCC | ?>8% | 10% |
| BRCA1 | 65% | 40% |
| BRCA2 | 45% | 25% |



- CA125
- TVS
- Only 85% of all and 50% of early ovarian cancers will have raised CA125
- False positives with endometriosis, fibroids etc
- There will be a proportion of interval cancers even if you screen annually
- Screening can be used where risk is increased



Ovarian aging and Menopause






Ovaries in sickness and health | 15 August 2014

- 94% get some symptoms, 25% get severe symptoms
- Hot flushes & sweats
 - 74% experience, most common symptom
- Headaches
- Tiredness
- Irritability
- Poor memory
- Sleep disturbance
- Depression, anxiety
- Loss of libido
- Dry skin
- Vaginal atrophy
- Osteoporosis.....








- Very effective at treating symptoms of menopause.
- Until recent studies (Women's Health Initiative and Million Women Study), HRT was widely used for long periods



| | RR (E2 only) | RR (E+P) |
|---------------|--------------|----------|
| CHD | 0.91 | 1.29 |
| Stroke | 1.39 | 1.41 |
| Breast Cancer | 0.77 | 1.26 |
| PE | 1.34 | 2.13 |
| Colorectal Ca | 1.08 | 0.63 |
| Hip Fracture | 0.61 | 0.66 |



Selected clinical outcomes by participant age



JAMA 2004;291:1701-1712

- Combined HRT increased breast cancer risk more that Oestrogen only HRT
- Risk increases with duration of HRT
- Risk seems to go back to normal within 5 y of stopping HRT






Figure 5: Standardised incidence rates for endometrial cancer per 1000 women in the study cohort over a 5-year period, according to body-mass index and type of HRT last used

- Risk in current users is 3-4 x higher than in non-users
 - one case in 5000 users per year
- The baseline risk of VTE between the ages of 50 and 70 is higher
- Increased risk appears to be concentrated in new users
- VTE risk is not increased with transdermal E (oral 3.5 vs TRD 0.9) ESTHER study - Lancet 2003;362:428-432



- An increase in breast cancer risk is related to
 - the duration of use and
 - concurrent use of progestogens
- **Transdermal oestrogen** have different metabolic profiles and side-effects (VTE risk)
- → Mirena + Transdermal Oestrogen



Thank You

London Gynaecology Ltd The Portland Hospital 212 Great Portland Street London W1W 5QN

T : 0207 10 11 700 F : 0207 69 10 394

contact@london-gynaecology.com

www.london-gynaecology.com

15/08/2014

